Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease

Chien Yi Hsu, Wei Kung Tseng, Yen Wen Wu, Tsung Hsien Lin, Hung I. Yeh, Kuan Cheng Chang, Ji Hung Wang, Ruey Hsing Chou, Chun Yao Huang, Po Hsun Huang, Hsin Bang Leu, Wei Hsian Yin, Chau Chung Wu, Shing Jong Lin, Jaw Wen Chen

研究成果: 雜誌貢獻文章

摘要

Objective- Basic research indicates that TNFSF14 (tumor necrosis factor superfamily 14) may be involved in the pathogenesis of atherosclerosis. Given the requirements of new biomarkers for risk classification in coronary artery disease (CAD), we conducted a longitudinal analysis to investigate if TNFSF14 levels are associated with the risk of cardiovascular events among patients with stable CAD. Approach and Results- In total, 894 patients with CAD were enrolled in a multicenter prospective study. The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome was the occurrence of all-cause death, nonfatal myocardial infarction, stroke, revascularization, and hospitalization because of angina or heart failure. During the mean follow-up period of 22±9 months, 32 patients reached the primary outcome and 166 patients reached the secondary outcome. Kaplan-Meier analysis showed that the event-free survival was significantly different in the first and fourth quartile groups in subjects categorized by TNFSF14 levels. In multivariate Cox proportional hazard regression analysis, TNFSF14 was independently associated with the risk of cardiovascular events after adjustment for various relevant factors (adjusted hazard ratio, 1.14; 95% CI, 1.04-1.25). In the validation cohort of 126 multivessel patients with CAD, TNFSF14 was confirmed to provide good prognostic predictive value for composite cardiovascular events (adjusted hazard ratio, 1.11; 95% CI, 1.04-1.19). Conclusions- This is the first study to demonstrate that increased TNFSF14 levels were independently associated with the occurrence of cardiovascular events in patients with stable CAD. Future studies are worthy to validate if TNFSF14 could be a novel prognostic biomarker for CAD outcomes over different populations.
原文英語
頁(從 - 到)1240-1252
頁數13
期刊Arteriosclerosis, Thrombosis, and Vascular Biology
39
發行號6
DOIs
出版狀態已發佈 - 六月 1 2019

指紋

Coronary Artery Disease
Tumor Necrosis Factor-alpha
Biomarkers
Stroke
Myocardial Infarction
Kaplan-Meier Estimate
Multicenter Studies
Disease-Free Survival
Cause of Death
Atherosclerosis
Hospitalization
Heart Failure
Regression Analysis
Prospective Studies
Research
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

引用此文

Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease. / Hsu, Chien Yi; Tseng, Wei Kung; Wu, Yen Wen; Lin, Tsung Hsien; Yeh, Hung I.; Chang, Kuan Cheng; Wang, Ji Hung; Chou, Ruey Hsing; Huang, Chun Yao; Huang, Po Hsun; Leu, Hsin Bang; Yin, Wei Hsian; Wu, Chau Chung; Lin, Shing Jong; Chen, Jaw Wen.

於: Arteriosclerosis, Thrombosis, and Vascular Biology, 卷 39, 編號 6, 01.06.2019, p. 1240-1252.

研究成果: 雜誌貢獻文章

Hsu, CY, Tseng, WK, Wu, YW, Lin, TH, Yeh, HI, Chang, KC, Wang, JH, Chou, RH, Huang, CY, Huang, PH, Leu, HB, Yin, WH, Wu, CC, Lin, SJ & Chen, JW 2019, 'Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease', Arteriosclerosis, Thrombosis, and Vascular Biology, 卷 39, 編號 6, 頁 1240-1252. https://doi.org/10.1161/ATVBAHA.118.312166
Hsu, Chien Yi ; Tseng, Wei Kung ; Wu, Yen Wen ; Lin, Tsung Hsien ; Yeh, Hung I. ; Chang, Kuan Cheng ; Wang, Ji Hung ; Chou, Ruey Hsing ; Huang, Chun Yao ; Huang, Po Hsun ; Leu, Hsin Bang ; Yin, Wei Hsian ; Wu, Chau Chung ; Lin, Shing Jong ; Chen, Jaw Wen. / Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease. 於: Arteriosclerosis, Thrombosis, and Vascular Biology. 2019 ; 卷 39, 編號 6. 頁 1240-1252.
@article{344bc2210f1a4c63a7f36f3083b53c14,
title = "Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease",
abstract = "Objective- Basic research indicates that TNFSF14 (tumor necrosis factor superfamily 14) may be involved in the pathogenesis of atherosclerosis. Given the requirements of new biomarkers for risk classification in coronary artery disease (CAD), we conducted a longitudinal analysis to investigate if TNFSF14 levels are associated with the risk of cardiovascular events among patients with stable CAD. Approach and Results- In total, 894 patients with CAD were enrolled in a multicenter prospective study. The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome was the occurrence of all-cause death, nonfatal myocardial infarction, stroke, revascularization, and hospitalization because of angina or heart failure. During the mean follow-up period of 22±9 months, 32 patients reached the primary outcome and 166 patients reached the secondary outcome. Kaplan-Meier analysis showed that the event-free survival was significantly different in the first and fourth quartile groups in subjects categorized by TNFSF14 levels. In multivariate Cox proportional hazard regression analysis, TNFSF14 was independently associated with the risk of cardiovascular events after adjustment for various relevant factors (adjusted hazard ratio, 1.14; 95{\%} CI, 1.04-1.25). In the validation cohort of 126 multivessel patients with CAD, TNFSF14 was confirmed to provide good prognostic predictive value for composite cardiovascular events (adjusted hazard ratio, 1.11; 95{\%} CI, 1.04-1.19). Conclusions- This is the first study to demonstrate that increased TNFSF14 levels were independently associated with the occurrence of cardiovascular events in patients with stable CAD. Future studies are worthy to validate if TNFSF14 could be a novel prognostic biomarker for CAD outcomes over different populations.",
keywords = "atherosclerosis, C-reactive protein, coronary artery disease, myocardial infarction, tumor necrosis factor",
author = "Hsu, {Chien Yi} and Tseng, {Wei Kung} and Wu, {Yen Wen} and Lin, {Tsung Hsien} and Yeh, {Hung I.} and Chang, {Kuan Cheng} and Wang, {Ji Hung} and Chou, {Ruey Hsing} and Huang, {Chun Yao} and Huang, {Po Hsun} and Leu, {Hsin Bang} and Yin, {Wei Hsian} and Wu, {Chau Chung} and Lin, {Shing Jong} and Chen, {Jaw Wen}",
year = "2019",
month = "6",
day = "1",
doi = "10.1161/ATVBAHA.118.312166",
language = "English",
volume = "39",
pages = "1240--1252",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Circulating TNFSF14 (Tumor Necrosis Factor Superfamily 14) Predicts Clinical Outcome in Patients With Stable Coronary Artery Disease

AU - Hsu, Chien Yi

AU - Tseng, Wei Kung

AU - Wu, Yen Wen

AU - Lin, Tsung Hsien

AU - Yeh, Hung I.

AU - Chang, Kuan Cheng

AU - Wang, Ji Hung

AU - Chou, Ruey Hsing

AU - Huang, Chun Yao

AU - Huang, Po Hsun

AU - Leu, Hsin Bang

AU - Yin, Wei Hsian

AU - Wu, Chau Chung

AU - Lin, Shing Jong

AU - Chen, Jaw Wen

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Objective- Basic research indicates that TNFSF14 (tumor necrosis factor superfamily 14) may be involved in the pathogenesis of atherosclerosis. Given the requirements of new biomarkers for risk classification in coronary artery disease (CAD), we conducted a longitudinal analysis to investigate if TNFSF14 levels are associated with the risk of cardiovascular events among patients with stable CAD. Approach and Results- In total, 894 patients with CAD were enrolled in a multicenter prospective study. The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome was the occurrence of all-cause death, nonfatal myocardial infarction, stroke, revascularization, and hospitalization because of angina or heart failure. During the mean follow-up period of 22±9 months, 32 patients reached the primary outcome and 166 patients reached the secondary outcome. Kaplan-Meier analysis showed that the event-free survival was significantly different in the first and fourth quartile groups in subjects categorized by TNFSF14 levels. In multivariate Cox proportional hazard regression analysis, TNFSF14 was independently associated with the risk of cardiovascular events after adjustment for various relevant factors (adjusted hazard ratio, 1.14; 95% CI, 1.04-1.25). In the validation cohort of 126 multivessel patients with CAD, TNFSF14 was confirmed to provide good prognostic predictive value for composite cardiovascular events (adjusted hazard ratio, 1.11; 95% CI, 1.04-1.19). Conclusions- This is the first study to demonstrate that increased TNFSF14 levels were independently associated with the occurrence of cardiovascular events in patients with stable CAD. Future studies are worthy to validate if TNFSF14 could be a novel prognostic biomarker for CAD outcomes over different populations.

AB - Objective- Basic research indicates that TNFSF14 (tumor necrosis factor superfamily 14) may be involved in the pathogenesis of atherosclerosis. Given the requirements of new biomarkers for risk classification in coronary artery disease (CAD), we conducted a longitudinal analysis to investigate if TNFSF14 levels are associated with the risk of cardiovascular events among patients with stable CAD. Approach and Results- In total, 894 patients with CAD were enrolled in a multicenter prospective study. The primary outcome was the occurrence of cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary outcome was the occurrence of all-cause death, nonfatal myocardial infarction, stroke, revascularization, and hospitalization because of angina or heart failure. During the mean follow-up period of 22±9 months, 32 patients reached the primary outcome and 166 patients reached the secondary outcome. Kaplan-Meier analysis showed that the event-free survival was significantly different in the first and fourth quartile groups in subjects categorized by TNFSF14 levels. In multivariate Cox proportional hazard regression analysis, TNFSF14 was independently associated with the risk of cardiovascular events after adjustment for various relevant factors (adjusted hazard ratio, 1.14; 95% CI, 1.04-1.25). In the validation cohort of 126 multivessel patients with CAD, TNFSF14 was confirmed to provide good prognostic predictive value for composite cardiovascular events (adjusted hazard ratio, 1.11; 95% CI, 1.04-1.19). Conclusions- This is the first study to demonstrate that increased TNFSF14 levels were independently associated with the occurrence of cardiovascular events in patients with stable CAD. Future studies are worthy to validate if TNFSF14 could be a novel prognostic biomarker for CAD outcomes over different populations.

KW - atherosclerosis

KW - C-reactive protein

KW - coronary artery disease

KW - myocardial infarction

KW - tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85066509638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066509638&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.118.312166

DO - 10.1161/ATVBAHA.118.312166

M3 - Article

C2 - 30943772

AN - SCOPUS:85066509638

VL - 39

SP - 1240

EP - 1252

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 6

ER -